IMMUNOVANT, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
IMMUNOVANT, INC. (IMVT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $13.45 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- IMMUNOVANT, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-06-30 was $13.45, a 92.97% increase year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-06-30 was $6.97, a 22.90% decline year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-06-30 was $9.04, a 23.67% increase year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-06-30 was $7.31, a 282.72% increase year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2026 was $8.48, a 13.98% increase from fiscal 2025.
- IMMUNOVANT, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $7.44, a 1.92% increase from fiscal 2024.
- IMMUNOVANT, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $7.30, a 5.44% decline from fiscal 2023.
- IMMUNOVANT, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $7.72.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.45 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $8.48 10-K · filed 2026-05-20 | |||
| 2025-12-31 | $8.44 10-Q · filed 2026-02-06 | |||
| 2025-09-30 | $7.62 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $6.97 10-Q · filed 2025-08-11 | |||
| 2025-03-31 | $7.44 10-K · filed 2025-05-29 | |||
| 2024-12-31 | $7.87 10-Q · filed 2025-02-06 | |||
| 2024-09-30 | $8.65 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $9.04 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | $7.30 10-K · filed 2024-05-29 | |||
| 2023-12-31 | $7.39 10-Q · filed 2024-02-12 | |||
| 2023-09-30 | $7.98 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $7.31 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $7.72 10-K · filed 2023-05-22 | |||
| 2022-12-31 | $7.35 10-Q · filed 2023-02-03 | |||
| 2022-09-30 | $1.91 10-Q · filed 2022-11-04 | |||
| 2022-06-30 | $1.91 10-Q · filed 2022-08-05 | |||
| 2021-03-31 | $8.57 10-K · filed 2021-06-01 | |||
| 2020-12-31 | $8.57 10-Q · filed 2021-02-16 | |||
| 2020-09-30 | $4.31 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | $2.64 10-Q · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |